A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

Pediatrics

Volumn 121, Issue 1, 2008, Pages

  Biederman, Joseph ^a   Melmed, Raun D ^b   Patel, Anil ^c   McBurnett, Keith ^d   Konow, Jennifer ^e   Lyne, Andrew ^f   Scherer, Noreen ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Melmed Center   (United States)

^c Psychiatric Centers at San Diego   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Kendle International Inc   (United States)

^f Shire Pharmaceuticals   (United Kingdom)

^g SHIRE   (United States)

Author keywords

2 adrenoceptor agonist; ADHD; Attention deficit hyperactivity disorder; Guanfacine; Nonstimulant; SPD503; Stimulant

Indexed keywords

GUANFACINE; PLACEBO;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT HYPERACTIVITY DISORDER RATING SCALE IV; BLOOD PRESSURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONNERS' PARENT RATING SCALE REVISED:SHORT FORM; CONNERS' TEACHER RATING SCALE-REVISED:SHORT FORM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LETHARGY; MALE; MULTICENTER STUDY; NAUSEA; PARENTS' GLOBAL ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VOMITING; XEROSTOMIA;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GUANFACINE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 38049049166     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-3695     Document Type: Article

References (36)

1. Olfson M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care. 2004;10(suppl 4):S117-S124
2. Wolraich ML, Hannah JN, Pinnock TY, Baumgaertel A, Brown J. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry. 1996;35:319-324
3. Shaffer D, Fisher P, Dulcan MK, et al. The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA Study. Methods for the Epidemiology of Child and Adolescent Mental Disorders Study. J Am Acad Child Adolesc Psychiatry. 1996;35:865-877
4. Bird HR, Canino G, Rubio-Stipec M, et al. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico: the use of combined measures. Arch Gen Psychiatry. 1988;45:1120-1126
5. Crenshaw TM, Kavale K, Forness SR. Attention deficit hyperactivity disorder and the efficacy of stimulant medication: a meta analysis. In: Scruggs TE, Mataro M, eds. Advances in Learning and Behavioral Disabilities. Greenwich, CT: JAI Press; 1999:135-165
6. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit- hyperactivity disorder. N Engl J Med. 1999;340:780-788
7. Gillberg C, Melander H, von Knorring AL, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54:857-864
8. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder: Multimodal Treatment Study of Children With ADHD. Arch Gen Psychiatry. 1999;56:1073-1086
9. Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA. Stimulant medications precipitate Tourette's syndrome. JAMA. 1982;247:1168-1169
10. Lipkin PH, Goldstein IJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med. 1994;148:859-861
11. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86:184-192
12. Borcherding BG, Keysor CS, Rapoport JL, Elia J, Amass J. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? Psychiatry Res. 1990;33:83-94
13. Garfinkel BD, Wender PH, Sloman L, O'Neill I. Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Psychiatry. 1983;22:343-348
14. Casat CD, Pleasants DZ, Van Wyck FJ. A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull. 1987;23:120-122
15. Riddle MA, Bernstein GA, Cook EH, Leonard HL, March JS, Swanson JM. Anxiolytics, adrenergic agents, and naltrexone. J Am Acad Child Adolesc Psychiatry. 1999;38:546-556
16. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:50-54
17. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila). 2000;39:15-25
18. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry. 1985;24:617-629
19. Hunt RD, Capper L, O'Connell P. Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol. 1990;1:87-102
20. Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci. 1988;8:4287-4298
21. Uhlen S, Wikberg JE. Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991;202:235-243
22. Newcorn JH, Schulz K, Harrison M, DeBellis MD, Udarbe JK, Halperin JM. Alpha 2 adrenergic agonists: neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin North Am. 1998;45:1099-1022, viii
23. Sorkin EM, Heel RC. Guanfacine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs. 1986;31:301-336
24. Horrigan JP, Barnhill LJ. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol. 1995;5:215-223
25. Kugler J, Seus R, Krauskopf R, Brecht HM, Raschig A. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. Br J Clin Pharmacol. 1980;10(suppl 1):71S-80S
26. Balldin J, Berggren U, Eriksson E, Lindstedt G, Sundkler A. Guanfacine as an alpha-2-agonist inducer of growth hormone secretion: a comparison with clonidine. Psychoneuroendocrinology. 1993;18:45-55
27. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry. 1995;34:1140-1146
28. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1067-1074
29. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21:223-228
30. Center for Drug Evaluation and Research. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Rockville, MD: Food and Drug Administration, US Department of Health and Human Services; 2005. Available at: www.fda.gov/cder/guidance/6922fnl.htm. Accessed December 7, 2006
31. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1). Available at: www.pediatrics.org/cgi/ content/full/114/1/e1
32. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5). Available at: www.pediatrics.org/cgi/content/full/108/5/e83
33. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901
34. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63:1140-1147
35. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005;116(6). Available at: www.pediatrics.org/cgi/content/full/116/6/e777
36. Spencer T, Biederman J, Heiligenstein J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11(3);251-265